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Abstract
Background
Spontaneous abortions, intrauterine growth restriction, and preeclampsia are thought to be
caused by defective placentation and are associated with increased risk of adverse out-
comes in subsequent pregnancies. However, it is not known whether the recurrence of
adverse outcomes is associated with the recurrence of placental pathology. We hypothe-
sized that recurrent maternal vascular malperfusion (MVM) underlies the recurrence of
adverse outcomes.
Methods
Using data from the National Collaborative Perinatal Project, we assessed the recurrence of
pregnancy complications and MVM lesions (N = 3865), associations between a history of
spontaneous abortions and MVM lesions or adverse outcomes in subsequent pregnancies
(N = 8312), and whether the recurrence of pregnancy complications occurred independently
of the presence of MVM lesions.
Results
The odds of an MVM lesion were higher for a woman who had had an MVM lesion in a previ-
ous pregnancy (aOR = 1.6; 95% CI 1.3–1.9), although this was marginally non-significant
after adjusting for covariates such as gestational age, race and BMI. The odds of pre-
eclampsia, a small-for-gestational-age infant, premature delivery and early pregnancy loss
were 2.7–5.0 times higher if there had been that same adverse outcome in a previous preg-
nancy. A history of spontaneous abortions was associated with higher risk of a small-for-
gestational-age baby (aOR = 2.4; 95% CI 1.7–3.4) and prematurity (aOR = 5.1; 95% CI 2.3–
11.5 for extremely preterm), but not preeclampsia. The recurrence of adverse outcomes
was significant when restricting analyses to women without MVM lesions. Similarly, associa-
tions between adverse outcomes and previous spontaneous abortions were significant
when statistically controlling for the presence of MVM lesions, or excluding pregnancies with
MVM lesions.
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Conclusions
Women with adverse outcomes in one pregnancy are at higher risk of complications in sub-
sequent pregnancies. However, there is significant recurrence of adverse outcomes even in
the absence of MVM.
Introduction
Placental dysfunction is thought to underlie diverse adverse pregnancy outcomes, including spon-
taneous abortions, intrauterine growth restriction, and preeclampsia [1], with spontaneous abor-
tions and later pregnancy complications caused by different degrees of impaired placentation [2].
Consistent with this hypothesis, some circulating markers have been associated with both preg-
nancy loss and preeclampsia (e.g., PAPP-A [3–6]; sFlt-1, PlGF [7,8]). Furthermore, genetic poly-
morphisms in certain genes have been associated with both conditions (e.g., VEGF [9–12];
PAPP-A [13,14]; TNF-α [15,16]), potentially suggesting a common genetic susceptibility. Endo-
thelial dysfunction has been proposed as a mechanism that might underlie these shared risks [17].
Given the potential shared etiology between preeclampsia and pregnancy loss, many studies
have examined associations between adverse pregnancy outcomes in index pregnancies and
spontaneous abortions in previous or subsequent pregnancies. Some find associations between
the occurrence of spontaneous abortions and preeclampsia [2,18–23], low birthweight
[2,18,20,23–26] and prematurity [2,18,23–27], although not all of these outcomes are consis-
tently observed [28,29].
These studies have not examined the placental pathology that may underlie these associa-
tions, but impaired placentation is thought to result in maternal vascular malperfusion
(MVM) lesions [30], which are associated with pregnancy complications [31–35]. Indeed,
there are associations between MVM lesions in one pregnancy and the incidence of adverse
outcomes in a subsequent pregnancy [36,37]. However, the association between MVM in one
pregnancy and spontaneous abortion in another has not been investigated. Furthermore, it has
not been shown that the recurrence of adverse outcomes in different pregnancies is associated
with recurrent MVM pathology.
We hypothesized that certain factors predispose women to recurrent MVM, which increases
the risk of spontaneous abortions, preeclampsia, intrauterine growth restriction, and prematu-
rity, and that this mechanism underlies the previously observed associations between spontane-
ous abortions in one pregnancy and adverse outcomes in another. We therefore predicted that
(1) MVM lesions or pregnancy complications in one pregnancy will be associated with an
increased risk of MVM lesions or pregnancy complications in the subsequent pregnancy, (2)
previous spontaneous abortions will be associated with an increased risk of MVM lesions, (3)
previous spontaneous abortions will be associated with an increased risk of adverse outcomes,
and (4) pregnancies with MVM lesions will have a higher incidence of adverse outcomes.
Finally, if associations between spontaneous abortions and adverse outcomes are due to recur-
rent placental pathologies, we predict that (5) previous spontaneous abortions will not be associ-
ated with an increased risk of adverse outcomes independently of the presence of MVM lesions.
We tested our predictions using data from the National Collaborative Perinatal Project.
Materials and methods
The National Collaborative Perinatal Project (NCPP) has been described elsewhere [38], and
its data are publicly available (https://catalog.archives.gov/id/606622). As we have described
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previously [39], in over 90% of pregnancies, maternal race was categorized as white or black,
and so analyses were restricted to these two races. We used only singleton pregnancies where
offspring sex was assigned male or female; fetal and neonatal deaths were included, and cases
were not excluded on the basis of maternal health conditions or congenital abnormalities. We
excluded pregnancies where the gestational age was over 43 weeks; gestational age was calcu-
lated based on the last menstrual period to the nearest week. Within each gestational age cate-
gory (described below), birthweights and placental weights were corrected for maternal race,
offspring sex and gestational age using a general linear model, after first removing the top and
bottom 0.5% of raw birthweights and placenta weights within each gestational age category to
objectively exclude biologically implausible values [40]. Pregnancies ending before 24 weeks
were excluded from all analyses except those of spontaneous abortions.
Outcomes
To assess prematurity, we used a lower limit for gestational age based on the limit of viability
[41], but otherwise used World Health Organization categories, i.e., extremely preterm (24 to
27 weeks, inclusive), very preterm (28 to 32 weeks, inclusive), moderate to late preterm (32 to
37 weeks, inclusive) and term (38 to 43 weeks, inclusive). In addition to prematurity, outcomes
included spontaneous abortion (i.e., gestational age less than 20 weeks), small for gestational
age (SGA, i.e., corrected birthweight below the 10th percentile), preeclampsia (yes/no), survival
(categorized as fetal death, death between birth and 120 days of age, or survival past 120 days),
Apgar score at 1 and 5 minutes (categorized as 0–3, 4–6, or 7–10, where larger numbers are
better). For preeclampsia, the rare cases of eclampsia were categorized as “yes”, whereas “mild”
preeclampsia was categorized as “no” because MVM lesions are more strongly associated with
severe preeclampsia [30]. Preeclampsia was categorized as severe if one or more of the follow-
ing symptoms was present: systolic blood pressure of 160 mmHg or higher, diastolic blood
pressure of 110 mmHg or higher (on at least two occasions at least six hours apart), proteinuria
of 5 grams or more, oliguria (400 cc or less in 24 hours), cerebral or visual disturbances, or pul-
monary edema or cyanosis.
MVM lesions
The NCPP data were collected > 50 years ago, and a comparison of variables available in the
NCPP with lesions currently used to define MVM is provided in Table 1. MVM lesions
included the presence of decidua vessel thrombosis, fibrinoid or atheroma, excessive fibrin
deposition in the cytotrophoblast, at least one infarct measuring 3 cm or more, presence of
hemorrhage, and syncytium-nuclear clumping that is excessive for term in a term placenta, or
normal for term in a preterm placenta. While accelerated villous maturation is often included
as an MVM lesion [42], it is difficult to diagnose in term placentas [39], and so syncytial
clumping was used instead. We used two different approaches to establish evidence of MVM:
(A) corrected placenta weight below the 10th percentile and one of the MVM lesions described
above [33,43] (which we term “MVMnarrow”), or (B) one of the MVM lesions described, irre-
spective of placental weight [31,35] (which we term “MVMbroad”). Although not all of the
lesions currently used to define MVM were available in the NCPP data, there is substantial var-
iability in the criteria used among recent studies (Table 1), such that our study is as similar to
some recent studies as the recent studies are to each other. We did not assess MVM for pla-
centas with gestational age below 24 weeks, and so no analyses examined the association
between spontaneous abortion and MVM lesions. Placental data were collected at 12 institu-
tions. To reduce potential bias due to inconsistent collection of data, we excluded all data from
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3 institutions where placental pathology data were available for less than 75% percent of
pregnancies.
Covariates
Gestational age, maternal age, maternal race, maternal body mass index (BMI), smoking (yes/
no) and interpregnancy interval were included as covariates. Maternal BMI was categorized as
underweight (< 18.5), normal (18.5–25), overweight (>25–30) or obese (> 30). Interpreg-
nancy interval was defined as the period between the end of the previous pregnancy and the
last menstrual period before the current pregnancy, and was categorized as short (less than 18
months), medium (18 to 59 months, inclusive) or long (greater than 59 months), based on pre-
viously-reported associations with adverse outcomes [47,48].
Recurrence of outcomes and pathology
To examine the recurrence of outcomes and pathology, we included only women with more
than one singleton pregnancy in the dataset and compared the second eligible pregnancy in
the dataset with the first. These criteria yielded 5889 eligible women. Excluding 440 women for
whom the gestational age of the first and/ or second pregnancy was below 24 weeks, for which
we did not assess MVM, there were 5449 women; assessment of MVM was available for both
pregnancies for 3865 of these women. Comparison of characteristics of pregnancies with and
Table 1. Comparison of lesions currently used to define MVM and variables available in NCPP data.
Current MVM criteria NCPP variables
decidual vasculopathy[31,35,37,44,45], decidual vascular
thrombosis[31]; decidual arteriopathy[30,42]; arterial
thrombosis[42]
decidua vessel thrombosis
fibrinoid changes/necrosis in decidual vessels[31];
fibrinoid necrosis[42]
decidua vessel fibrinoid
acute atherosis[31,42], decidual vasculopathy atherosis
[43];
decidua vessel atheroma
increased perivillous fibrin[31]; increased perivillous
fibrin deposition[35,37]; increased intervillous fibrin
deposition[35,37]; fibrinoid deposition[44]
excessive fibrin deposition in the cytotrophoblast (as
defined in NCPP documentation, “this refers to the
fibrin or fibrinoid deposits which occur in
cytotrophoblast cells as term is approached”)
infarction[31,42]; villous infarction[35,37]; infarcts[44];
central (> 1 cm), full-thickness or multi-focal infarction
[43]; placental infarction[30]; placental infarcts[45];
macroscopic infarction >5% of the placental parenchyma
[46]; multifocal infarction[33]
at least one infarct measuring 3 cm or more
hypermature chorionic villi[31]; accelerated villous
maturation[30,31,42–46]; advanced villous maturation
[35,37]; increased syncytial knot prevalence[42];
abnormal placental villi[33]
syncytium-nuclear clumping that is excessive for term
in a term placenta, or normal for term in a preterm
placenta
low placental weight (placental weight<10th percentile)
[33,42–44,46]; placental hypoplasia[30,42]
corrected placenta weight below the 10th percentile
retroplacental hematoma[31]; retroplacental hemorrhage
[30,33,42]
presence of hemorrhage on maternal surface or
depressed area caused by hemorrhage
distal villous hypoplasia[30,42,46]; mural hypertrophy
[42]; chronic perivasculitis[42]; absence of spiral artery
remodeling [42]; persistence of intramural endovascular
trophoblast in the third trimester [42]; increased
circulating nucleated red blood cells (NRBC)[46];
ischemia and shock villi [46]; eosinophilic necrosis of
decidual arterial walls[43]
not described
https://doi.org/10.1371/journal.pone.0228664.t001
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without MVM data is provided in the Table in S1 Table, including both women with and with-
out more than one singleton pregnancy (study population described below). In the recurrence
dataset, only 18 index pregnancies had an interpregnancy interval greater than 59 months and
so these pregnancies were excluded from analyses involving interpregnancy interval.
Associations between previous spontaneous abortions, MVM lesions, and
outcomes
To examine associations between previous spontaneous abortions and outcomes, we com-
pared women with 3 or more pregnancy losses at less than 20 weeks, with women with no
prior losses (but at least one prior pregnancy), no record of sterility or infertility whose current
pregnancy was conceived in 6 months or less. In both groups, we excluded women with more
than 3 prior livebirths to ensure that the previous loss group included only women for whom
at least half of previous pregnancies were losses, and not women who had had multiple losses
simply as a result of numerous pregnancies. Where a woman had more than one pregnancy
included in the NCCP, we included only her first study pregnancy. These criteria yielded
18077 eligible pregnancies. Excluding 3638 pregnancies with gestational age below 24 weeks
(for which we did not assess MVM), there were 14439 pregnancies, of which assessment of
MVM was available for 11753; comparison of characteristics of pregnancies with and without
missing placental data is provided in the Table in S1 Table. For analyses including previous
losses, 8312 pregnancies were available; 3199 pregnancies with 1 or 2 prior losses were
excluded because we compared women with 3 or more pregnancy losses with no prior losses.
Statistical analyses
Birthweight and placental weight were corrected for maternal race, offspring sex and gesta-
tional age using a general linear model (proc GLM, SAS, Version 9.4). Pregnancy outcomes
and the presence of MVM lesions were analysed using logistic regression (proc LOGISTIC,
SAS, Version 9.4).
Results
Prediction 1: MVM lesions or pregnancy complications in one pregnancy
will be associated with an increased risk of MVM lesions or pregnancy
complications in the subsequent pregnancy
Among women with more than one singleton pregnancy in the dataset, MVMbroad lesions in
one pregnancy were associated with increased odds of MVMbroad lesions in the subsequent
pregnancy (aOR = 1.6), although after adjusting for covariates such as gestational age, race and
BMI, this was marginally non-significant (aOR = 1.2, P = 0.06, Table 2). Although the aOR for
MVMnarrow lesions was similar to that for MVMbroad lesions, the recurrence was not signifi-
cant, with or without adjustment for covariates, likely due to their very low frequency
(Table 2). Preeclampsia, SGA, prematurity, spontaneous abortion, and poor Apgar scores in
one pregnancy were associated with increased odds of the same adverse outcome occurring in
the subsequent pregnancy, even after adjusting for interpregnancy interval, gestational age,
maternal race, maternal BMI and smoking (Table 2). Adjusted odds ratios for the recurrence
of adverse outcomes were highest for preeclampsia, SGA and prematurity (5.0, 4.6 and 3.7
respectively) and lowest for Apgar scores at 1 minute (1.4). Fetal and neonatal death did not
show significant recurrence after correction for covariates, of which gestational age and race
were significant (Table 2).
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Table 2. Recurrence of MVM and pregnancy outcomes between pregnancies.
Occurrence in
previous
pregnancy1
Odds
ratio2
P-value Adjusted odds
ratio3
P-value Other significant terms in model4
Occurrence in index
pregnancy
Yes #
(%)
No # (%) (95% CI) (95% CI)
MVMnarrow Yes 2 (3.2) 60 (96.8) 1.5 (0.4–
6.1)
0.59 1.4 (0.3–5.9) 0.65 Gestational age (P < 0.0001); Race
(P = 0.006)
No 84 (2.2) 3719
(97.8)
MVMbroad Yes 261
(29.8)
616
(70.2)
1.6 (1.3–
1.9)
0.0001 1.2 (1.0–1.5) 0.06 Gestational age (P < 0.0001); Race
(P = 0.02); BMI (P = 0.02)
No 655
(21.1)
2446
(78.9)
Preeclampsia Yes 18
(19.8)
73 (80.2) 6.5 (3.8–
11.2)
0.0001 5.0 (2.9–8.7) 0.0001 Race (P < 0.0001); BMI (P < 0.002)
No 170
(3.6)
4498
(96.4)
SGA Yes 145
(31.1)
322
(68.9)
5.2 (4.2–
6.5)
0.0001 4.6 (3.7–5.8) 0.0001 Smoking (P < 0.0001)
No 385
(8.0)
4440
(92.0)
Prematurity Extreme 32
(40.5)
47 (59.5) 4.3 (2.7–
6.8)
0.0001 3.7 (2.3–5.9) 0.0001 Race (P < 0.0001); BMI (P = 0.0004)
Very 91
(43.3)
119
(56.7)
4.8 (3.6–
6.4)
3.8 (2.8–5.1)
Moderate 369
(40.7)
537
(59.3)
4.3 (3.7–
5.1)
3.7 (3.1–4.3)
Term 583
(13.7)
3671
(86.3)
Spontaneous abortion
before 20 weeks
Yes 15 (9.2) 149
(90.9)
3.0 (1.7–
5.3)
0.0001 2.7 (1.5–5.1) 0.001 Race (P = 0.04); BMI (P = 0.02)
No 184
(3.2)
5541
(96.8)
Survival Fetal death 11
(12.6)
76 (87.4) 3.8 (2.0–
7.2)
0.0001 2.3 (1.0–5.0) 0.11 Gestational age (P < 0.0001); Race
(P = 0.01)
Death before 120 days 10 (8.0) 115
(92.0)
2.3 (1.2–
4.4)
1.5 (0.7–3.0)
Survival past 120 days 193
(3.7)
5044
(96.3)
Apgar score at 1 minute 0–3 55
(28.4)
139
(71.6)
1.6 (1.2–
2.2)
0.0002 1.5 (1.1–2.1) 0.0006 Gestational age (P < 0.0001)
4–6 147
(25.7)
424
(74.3)
1.4 (1.1–
1.7)
1.4 (1.2–1.7)
7–10 747
(19.8)
3028
(80.2)
Apgar score at 5 minutes 0–3 9 (14.8) 52 (85.3) 3.9 (1.9–
8.0)
0.0002 3.1 (1.4–6.6) 0.006 Gestational age (P < 0.0001)
4–6 9 (8.3) 99 (91.7) 2.0 (1.0–
4.1)
1.8 (0.9–3.6)
7–10 195
(4.3)
4350
(95.7)
1 For outcomes with multiple levels of adverse outcomes, all levels of adverse outcome (e.g., extreme, very and moderate preterm) were combined for the previous
pregnancy.
2 All odds ratios were calculated as the odds of the adverse outcome relative to the odds of the best outcome where there were multiple levels of adverse outcomes.
3 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal race, maternal BMI and smoking. Analyses of
prematurity and spontaneous abortion before 20 weeks did not include gestational age.
4 Adjusted odds ratios for other terms are provided in the Table in S3 Table.
https://doi.org/10.1371/journal.pone.0228664.t002
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To assess whether the recurrence of pregnancy complications occurred in the absence of
recurrent MVM lesions, we restricted analyses to women who showed no MVM lesion in
either pregnancy. Preeclampsia, SGA and prematurity in one pregnancy were associated with
increased odds of the same adverse outcome occurring in the subsequent pregnancy after
adjusting for covariates (Table in S2 Table). Moreover, the adjusted odds ratios were similar
whether women with MVM lesions were excluded (Table in S2 Table) or not (Table 2) for the
recurrence of preeclampsia (excluding: 4.9–5.2 vs. not excluding: 5.0), SGA (4.1–4.6 vs. 4.6)
and prematurity (3.3–8.7 vs. 3.7). Similar results were observed whether using our “narrow” or
“broad” criteria for MVM lesions, although the recurrence of Apgar scores was not statistically
significant when excluding pregnancies showing MVMbroad lesions (Table in S2 Table). Given
the broader inclusion criteria, MVMbroad lesions were frequent (Table 2) and so their exclusion
reduced sample sizes substantially, reducing statistical power.
Prediction 2: Previous spontaneous abortions will be associated with an
increased risk of MVM lesions in index pregnancy
We compared women with 3 or more pregnancy losses at less than 20 weeks with women with
no prior losses. Previous spontaneous abortions were associated with increased odds of
MVMnarrow lesions (aOR = 2.2), but not MVMbroad lesions (aOR = 0.9), in the index pregnancy
when adjusting for interpregnancy interval, gestational age, maternal age, maternal race,
maternal BMI and smoking (Table 3).
Prediction 3: Previous spontaneous abortions will be associated with an
increased risk of adverse outcomes in index pregnancy
Adjusting for covariates, previous spontaneous abortions were associated with increased odds
of SGA (aOR = 2.4), extremely (aOR = 5.1) or very preterm birth (aOR = 2.2), spontaneous
abortion before 20 weeks (aOR = 2.1), fetal death at 24 weeks or later (aOR = 4.6), and low
Apgar scores at 1 (aOR = 1.8) and 5 minutes (aOR = 4.5; Table 3). Previous spontaneous abor-
tions were not associated with increased odds of preeclampsia (aOR = 1.1; Table 3).
Prediction 4: Pregnancies with MVM lesions will have a higher incidence of
adverse outcomes
The presence of MVM, defined using our “narrow” criteria, was associated with increased
odds of preeclampsia (aOR = 2.6), SGA (aOR = 11.5), prematurity (aOR = 3.9–4.7), and fetal
death (aOR = 12.5), before and after adjustment for covariates (Table 4). Using our “broad”
criteria, MVM lesions were associated with higher odds of SGA (aOR = 1.2) and prematurity
(aOR = 9.8–24.7), and fetal death (aOR = 2.1) but not preeclampsia or Apgar scores after
adjustment for covariates (Table 5).
Prediction 5: Previous spontaneous abortions will not be associated with an
increased risk of adverse outcomes independently of the presence of MVM
lesions
Adjusting for covariates including the presence of MVM lesions, previous spontaneous abor-
tions were associated with increased odds of SGA, prematurity and fetal death at 24 weeks or
later, and lower Apgar scores at 1 and 5 minutes (Table 6). Results were similar whether using
our narrow or broad criteria to define the presence of MVM lesions. Adjusted odds ratios for
the association with previous spontaneous abortions were similar whether adjusting for the
presence of MVM lesions (Table 6) or not (Table 3) for SGA (adjusting for MVM lesions: 1.9–
Pregnancy complications recur independently of maternal vascular malperfusion lesions
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Table 3. Associations between previous spontaneous abortions and pregnancy outcomes.
Previous
spontaneous
abortions
Odds
ratio1
P-
value
Adjusted odds
ratio2
P-
value
Other significant terms in model3
Occurrence in index
pregnancy
Yes #
(%)
No #
(%)
(95% CI) (95% CI)
MVMnarrow Yes 12
(7.0)
160
(93.0)
3.0 (1.6–
5.5)
0.0003 2.2 (1.2–4.4) 0.02 Interpregnancy interval (P = 0.04); Gestational age
(P < 0.0001)
No 198
(2.4)
7942
(97.6)
MVMbroad Yes 53
(2.7)
1879
(97.3)
1.1 (0.8–
1.5)
0.60 0.9 (0.6–1.3) 0.51 Gestational age (P < 0.0001)
No 165
(2.5)
6368
(97.5)
Preeclampsia Yes 8 (3.3) 234
(96.7)
1.4 (0.7–
2.8)
0.38 1.1 (0.5–2.4) 0.72 Age (P = 0.001); Gestational age (P = 0.03); Race
(P < 0.0001); BMI (P < 0.0001); Smoking
(P = 0.03)
No 224
(2.4)
9056
(97.6)
SGA Yes 50
(5.9)
801
(94.1)
2.8 (2.0–
3.9)
0.0001 2.4 (1.7–3.4) 0.0001 Age (P = 0.004); Gestational age (P = 0.008); BMI
(P < 0.0001); Smoking (P < 0.0001)
No 199
(2.2)
8983
(97.8)
Prematurity Extreme 9 (8.7) 95
(91.3)
3.8 (1.9–
7.5)
0.0009 5.1 (2.3–11.5) 0.0001 Age (P = 0.02); Race (P < 0.0001); BMI
(P < 0.0001); Smoking (P < 0.0001)
Very 13
(4.1)
302
(95.9)
1.7 (1.0–
3.0)
2.2 (1.2–4.1)
Moderate 41
(2.6)
1522
(97.4)
1.1 (0.8–
1.5)
1.3 (0.9–1.8)
Term 201
(2.5)
7966
(97.5)
Spontaneous abortion
before 20 weeks
Yes 21
(10.8)
174
(89.2)
4.4 (2.8–
7.0)
0.0001 2.1 (1.2–3.6) 0.005 Interpregnancy interval (P = 0.0002); Age
(P < 0.0001); BMI (P = 0.03); Smoking (P = 0.05)
No 272
(2.7)
9932
(97.3)
Survival Fetal death 18
(13.3)
117
(86.7)
6.2 (3.7–
10.3)
0.0001 4.6 (2.3–9.0) 0.0001 Interpregnancy interval (P = 0.01); Gestational age
(P < 0.0001); Race (P = 0.006)
Death before 120
days
7 (3.5) 195
(96.5)
1.4 (0.7–
3.1)
1.3 (0.6–3.0)
Survival past 120
days
239
(2.4)
9573
(97.6)
Apgar score at 1 minute 0–3 19
(4.5)
405
(95.5)
2.1 (1.3–
3.4)
0.001 1.8 (1.1–3.0) 0.02 Interpregnancy interval (P = 0.002); Age (P = 0.03);
Gestational age (P < 0.0001); Race (P < 0.03)
4–6 39
(3.4)
1110
(96.6)
1.6 (1.1–
2.2)
1.5 (1.0–2.1)
7–10 166
(2.2)
7428
(97.8)
Apgar score at 5
minutes
0–3 9 (8.1) 102
(91.9)
3.6 (1.8–
7.2)
0.001 4.5 (2.0–10.1) 0.0007 Interpregnancy interval (P = 0.02); Gestational age
(P < 0.0001)
4–6 4 (1.6) 240
(98.4)
0.7 (0.2–
1.8)
0.6 (0.2–1.6)
7–10 216
(2.4)
8754
(97.6)
1 All odds ratios were calculated as the odds of the adverse outcome relative to the odds of the best outcome where there were multiple levels of adverse outcomes.
2 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal age, maternal race, maternal BMI and smoking. Analyses
of prematurity and spontaneous abortion before 20 weeks did not include gestational age.
3 Adjusted odds ratios for other terms are provided in the Table in S4 Table.
https://doi.org/10.1371/journal.pone.0228664.t003
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2.2 vs. not adjusting: 2.4), prematurity (2.9–3.1 vs. 2.2 for very premature birth), and fetal
death (4.5–5.0 vs. 4.6). Previous spontaneous abortions were not associated with preeclampsia
with (Table 6) or without (Table 3) inclusion of MVM lesions (defined using narrow or broad
criteria) in the model.
Restricting analyses to pregnancies with no signs of MVM lesions, previous spontaneous
abortions remained associated with increased odds of SGA, prematurity, and lower Apgar
scores (Table 7). However, the association between previous spontaneous abortions and fetal
death at 24 weeks or later was no longer significant when removing pregnancies with MVM
lesions (Table 7). Similar results were observed whether using our “narrow” or “broad” criteria
Table 4. Associations between MVMnarrow lesions and pregnancy outcomes.
MVMnarrow Odds
ratio1
P-
value
Adjusted odds
ratio2
P-
value
Other significant terms in model
Occurrence in
pregnancy
Yes #
(%)
No # (%) (95% CI) (95% CI)
Preeclampsia Yes 14 (4.6) 294
(95.4)
2.4 (1.4–
4.1)
0.002 2.6 (1.5–4.6) 0.0009 Age (P < 0.0001); Race (P < 0.0001); BMI
(P < 0.0001); Smoking (P = 0.01)
No 213
(2.0)
10621
(98.0)
SGA Yes 115
(10.9)
943
(89.1)
10.2 (7.9–
13.3)
0.0001 11.5 (8.7–15.2) 0.0001 Age (P = 0.0003); Gestational age (P < 0.0001); BMI
(P < 0.0001); Smoking (P < 0.0001)
No 125
(1.2)
10495
(98.8)
Prematurity Extreme 6 (6.0) 94 (94.0) 4.5 (1.9–
10.6)
0.0001 4.7 (2.0–11.0) 0.0001 Age (P = 0.02); Race (P < 0.0001); BMI (P < 0.0001);
Smoking (P < 0.0001)
Very 21 (6.2) 318
(93.8)
4.7 (2.9–
7.6)
4.7 (2.9–7.8)
Moderate 89 (5.2) 1625
(94.8)
3.9 (3.0–
5.1)
3.9 (2.9–5.2)
Term 133
(1.4)
9467
(98.6)
Survival Fetal death 34
(26.0)
97 (74.0) 19.2
(12.7–
29.1)
0.0001 12.5 (7.8–19.9) 0.0001 Interpregnancy interval (P = 0.05); Age (P = 0.001);
Gestational age (P < 0.0001); Race (P = 0.008)
Death before 120
days
11 (4.7) 225
(95.3)
2.7 (1.4–
5.0)
1.7 (0.9–3.3)
Survival past 120
days
204
(1.8)
11182
(98.2)
Apgar score at 1
minute
0–3 20 (3.7) 526
(96.3)
2.2 (1.4–
3.5)
0.005 1.6 (1.0–2.7) 0.10 Interpregnancy interval (P = 0.002); Age (P = 0.008);
Gestational age (P < 0.0001); BMI (P < 0.02)
4–6 24 (1.6) 1436
(98.4)
1.0 (0.6–
1.5)
0.9 (0.6–1.4)
7–10 154
(1.7)
8820
(98.3)
Apgar score at 5
minutes
0–3 6 (4.6) 124
(95.4)
2.8 (1.2–
6.4)
0.0002 1.6 (0.6–4.1) 0.02 Interpregnancy interval (P = 0.02); Gestational age
(P < 0.0001)
4–6 13 (4.6) 272
(95.4)
2.8 (1.6–
4.9)
2.2 (1.2–3.9)
7–10 183
(1.7)
10556
(98.3)
1 All odds ratios were calculated as the odds of the adverse outcome relative to the odds of the best outcome where there were multiple levels of adverse outcomes.
2 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal age, maternal race, maternal BMI and smoking. Analyses
of prematurity did not include gestational age.
https://doi.org/10.1371/journal.pone.0228664.t004
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for MVM lesions (Table 7). Adjusted odds ratios were similar whether pregnancies with MVM
lesions were removed (Table 7) or not (Table 3) for SGA (excluding pregnancies with MVM
lesions: 1.8 vs. including: 2.4) and prematurity (2.7–3.8 vs. 2.2 for very premature birth).
Discussion
MVM lesions are thought to reflect placental dysfunction that may underlie spontaneous abor-
tions, preeclampsia and intrauterine growth restriction. We examined whether recurrence of
pathology might underlie the recurrence of adverse outcomes. The odds of an MVM lesion
were 1.6 times higher for a woman who had had an MVM lesion in a previous pregnancy,
Table 5. Associations between MVMbroad lesions and pregnancy outcomes.
MVMbroad Odds ratio
1 P-
value
Adjusted
odds ratio2
P-
value
Other significant terms in model
Occurrence in
pregnancy
Yes #
(%)
No # (%) (95% CI) (95% CI)
Preeclampsia Yes 83
(26.3)
232
(73.7)
1.3 (1.0–1.6) 0.09 1.2 (0.9–1.6) 0.24 Age (P < 0.0001); Race (P < 0.0001); BMI (P < 0.0001);
Smoking (P = 0.03)
No 2455
(22.3)
8576
(77.7)
SGA Yes 264
(24.3)
820
(75.7)
1.1 (1.0–1.3) 0.10 1.2 (1.0–1.4) 0.02 Interpregnancy interval (P = 0.03); Age (P = 0.0002);
Gestational age (P < 0.0005); BMI (P < 0.0001);
Smoking (P < 0.0001)
No 2388
(22.1)
8399
(77.9)
Prematurity Extreme 69
(68.3)
32 (31.7) 14.0 (9.2–
21.4)
0.0001 14.8 (9.6–
22.8)
0.0001 Race (P < 0.0001); BMI (P < 0.0001); Smoking
(P < 0.0001)
Very 272
(78.4)
75 (21.6) 23.6
(18.2 = 30.7)
24.7 (18.8–
32.3)
Moderate 1042
(59.6)
707
(40.4)
9.6 (8.6–10.7) 9.8 (8.8–11.1)
Term 1301
(13.3)
8473
(86.7)
Survival Fetal death 90
(62.5)
54 (37.5) 6.1 (4.3–8.5) 0.0001 2.1 (1.4–3.1) 0.0001 Age (P < 0.0001); Gestational age (P < 0.0001); Race
(P = 0.003)
Death before 120
days
100
(41.0)
144
(59.0)
2.5 (1.9–3.3) 0.7 (0.5–0.9)
Survival past 120
days
2494
(21.5)
9089
(78.5)
Apgar score at 1
minute
0–3 165
(29.6)
392
(70.4)
1.6 (1.3–1.9) 0.0001 1.0 (0.8–1.2) 0.53 Interpregnancy interval (P = 0.001); Age (P = 0.007);
Gestational age (P < 0.0001); BMI (P < 0.02)
4–6 349
(23.6)
1132
(76.4)
1.2 (1.0–1.3) 1.1 (0.9–1.3)
7–10 1918
(21.0)
7214
(79.0)
Apgar score at 5
minutes
0–3 54
(40.6)
79 (59.4) 2.5 (1.8–3.6) 0.0001 0.7 (0.4–1.0) 0.15 Interpregnancy interval (P = 0.02); Gestational age
(P < 0.0001)
4–6 93
(31.9)
199
(68.2)
1.7 (1.3–2.2) 0.9 (0.7–1.2)
7–10 2332
(21.4)
8586
(78.64)
1 All odds ratios were calculated as the odds of the adverse outcome relative to the odds of the best outcome where there were multiple levels of adverse outcomes.
2 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal age, maternal race, maternal BMI and smoking. Analyses
of prematurity did not include gestational age.
https://doi.org/10.1371/journal.pone.0228664.t005
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using our broad definition of MVM lesions, although this was marginally non-significant after
adjustment for covariates. The odds of an adverse outcome were 2.7–4.9 times higher if there
Table 6. Associations of previous spontaneous abortions and pregnancy outcomes including the presence of MVM lesions as a covariate.
Including MVMnarrow as a covariate Including MVMbroad as a covariate
Effect of previous spontaneous
abortions
Effect of MVM Effect of previous spontaneous
abortions
Effect of MVM
aOR1 P-value aOR1 P-value aOR1 P-value aOR1 P-value
Preeclampsia 1.0 (0.4–2.4) 0.98 3.5 (1.8–6.7) 0.0002 1.2 (0.5–2.7) 0.69 1.3 (0.9–1.9) 0.14
SGA 1.9 (1.3–2.9) 0.002 10.6 (7.5–15.0) 0.0001 2.2 (1.5–3.2) 0.0001 1.2 (1.0–1.5) 0.04
Prematurity 0.002 0.0001 0.0005 0.0001
Extreme 4.1 (1.3–12.5) 3.1 (0.9–10.2) 5.7 (2.0–16.4) 14.0 (8.3–23.4)
Very 2.9 (1.5–5.6) 4.0 (2.2–7.2) 3.1 (1.5–6.3) 29.7 (21.4–41.1)
Moderate 1.3 (0.8–1.9) 3.5 (2.5–4.9) 1.3 (0.8–2.1) 9.9 (8.6–11.3)
Survival 0.006 0.0001 0.0008 0.008
Fetal death 4.5 (1.8–11.3) 15.4 (8.6–27.6) 5.0 (2.2–11.6) 2.0 (1.2–3.4)
Death before 120 days 1.1 (0.4–2.8) 1.4 (0.6–3.3) 1.1 (0.4–2.7) 0.8 (0.5–1.1)
Apgar at 1 minute 0.03 0.18 0.02 0.14
0–3 1.6 (0.9–2.9) 1.8 (0.9–3.2) 1.8 (1.0–3.1) 1.3 (1.0–1.7)
4–6 1.6 (1.1–2.4) 0.9 (0.5–1.6) 1.6 (1.1–2.3) 1.1 (0.9–1.3)
Apgar at 5 minutes 0.0009 0.08 0.001 0.30
0–3 5.1 (2.0–12.5) 2.2 (0.8–6.2) 5.0 (2.0–12.2) 0.7 (0.4–1.1)
4–6 0.5 (0.2–1.7) 2.0 (0.9–4.1) 0.5 (0.2–1.7) 0.9 (0.6–1.3)
1 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal age, maternal race, maternal BMI and smoking. Analyses
of prematurity did not include gestational age.
https://doi.org/10.1371/journal.pone.0228664.t006
Table 7. Associations of previous spontaneous abortions and pregnancy outcomes excluding cases with MVM
lesions.
Excluding MVMnarrow lesions Excluding MVMbroad lesions
aOR1 P-value aOR1 P-value
Preeclampsia 0.8 (0.3–2.1) 0.71 1.0 (0.4–2.9) 0.96
SGA 1.8 (1.1–2.8) 0.01 1.8 (1.2–2.9) 0.01
Prematurity 0.003 0.003
Extreme 4.7 (1.5–14.3) 12.0 (2.3–63.5)
Very 2.7 (1.3–5.4) 3.8 (1.2–12.0)
Moderate 1.3 (0.8–1.9) 1.3 (0.7–2.3)
Survival 0.12 0.54
Fetal death 2.9 (1.0–8.8) 1.7 (0.3–9.1)
Death before 120 days 0.7 (0.2–2.2) 0.5 (0.1–2.4)
Apgar at 1 minute 0.03 0.04
0–3 1.6 (0.9–3.0) 1.9 (1.0–3.8)
4–6 1.6 (1.1–2.4) 1.6 (1.0–2.4)
Apgar at 5 minutes 0.03 0.15
0–3 3.5 (1.3–9.5) 3.2 (0.9–12.0)
4–6 0.5 (0.2–1.8) 0.5 (0.1–2.3)
1 Adjusted odds ratios are from logistic regression including interpregnancy interval, gestational age, maternal age,
maternal race, maternal BMI and smoking. Analyses of prematurity did not include gestational age.
https://doi.org/10.1371/journal.pone.0228664.t007
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had been that adverse outcome in a previous pregnancy. As described by others [2,18,20,23–
27], previous spontaneous abortions were associated with 2.4 times higher odds of SGA and
5.1 times higher odds of extreme prematurity. Furthermore, we also showed that previous
spontaneous abortions were associated with increased risk of low Apgar scores. However, we
did not find an association between previous spontaneous abortions and preeclampsia.
The presence of MVM lesions was associated with higher odds of preeclampsia, SGA, pre-
maturity, and fetal death, as previously observed [30], as well as low Apgar scores. These obser-
vations, largely consistent with previous work, led us to hypothesize that the associations
between previous spontaneous abortions and subsequent adverse outcomes, and the recur-
rence of the same adverse outcome, were due to the recurrence of MVM lesions. However, the
associations between previous spontaneous abortions and adverse outcomes generally
remained significant and similar in magnitude even when controlling for the presence MVM
lesions, or when removing pregnancies with MVM lesions. Furthermore, among women with
more than one pregnancy in the dataset, the recurrence of adverse outcomes was significant
when restricting analyses to women without MVM lesions in either pregnancy. These results
suggested that the recurrence of adverse outcomes, and the associations between spontaneous
abortions and adverse outcomes in subsequent pregnancies, can occur independently of recur-
rent MVM lesions. While it is possible that recurrent pathology did account for some cases of
recurrent adverse outcomes, the adjusted odds ratios for associations with previous abortions
and for the recurrence of adverse outcomes were generally not reduced by controlling for the
presence MVM lesions or removing pregnancies with MVM lesions, suggesting that a substan-
tial component of recurrence risk is independent of pathology. Previous studies have shown
that the presence of MVM in one pregnancy is associated with increased risk of adverse out-
come in a subsequent pregnancy [36,37,49]. Our results indicate that the MVM lesion itself
does not have to recur to result in an adverse outcome, and suggest that other, unmeasured
confounding factors may be responsible for these associations.
We used two different approaches described in the literature to define the presence of
MVM, differing only in whether low placental weight was required for diagnosis (MVMnarrow)
[33,43] or not (MVMbroad) [31,35]. The two approaches generally yielded similar results,
except that MVMnarrow lesions were associated with higher odds of preeclampsia whereas
MVMbroad lesions were not. These results suggest that the “narrow” approach provided a more
specific, informative diagnosis.
Approximately 2% of placentas showed MVMnarrow lesions whereas 23% showed
MVMbroad lesions. Our prevalence of MVMbroad lesions is lower than previous reports (30.5%
[35]; 35.7% [50]; 39.9% [31]; 46.7–49.7% [44]), perhaps because healthy pregnancies were less
likely to have been examined in some of these other studies. Our prevalence of MVMnarrow
lesions is similar to that in studies that used a similar definition (8.4% [33]; 0–4.2% including
ethnicities included in the present study [43]).
We acknowledge that our study used data collected> 50 years ago, and that assessment of
placental pathology has changed in that time. For example, the term distal villous hypoplasia
was not used in the histological assessment of the placentas. Despite this, our observed rates of
MVMnarrow are in the range of those of more recent studies, as discussed above. A strength of
the present study is that placental pathology was performed consistently and collected for
healthy, uncomplicated pregnancies, with pathology data available for over 80% of pregnan-
cies. Moreover, we reproduced the association between MVM lesions and preeclampsia
[31,33,35]. Furthermore, the lesions used to define MVM are not consistent among current
studies (Table 1), and some authors require lesions to be combined with low placental weight
whereas others do not, resulting in very different rates of MVM. We investigated both
approaches, and the criteria we used were very similar to some recent work. Finally, while the
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assessment of pathology has evolved, the biology underlying the pathology and the associations
between placental function and adverse outcomes are not expected to have changed.
Conclusions
Women with spontaneous abortions or other adverse outcomes in a previous pregnancy are at
higher risk of adverse outcomes in subsequent pregnancies. However, the recurrence of out-
comes thought to be associated with MVM lesions occurs even in the absence of placental
pathology. In many cases, the recurrence of an adverse outcomes may not be due to an intrin-
sic predisposition to a specific placental pathology, but rather may be caused by other aspects
of maternal physiology beyond the placenta.
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